Recent advances in the field allowed the identification of small molecules with potential to treat the basic defect in CF—either correctors, promoting the relocation of F508del-CFTR from the ER to the PM or potentiators, promoting channel activity (for variants already located at the PM). The gene discussed is CFTR; the disease is cystic fibrosis.